OmniSpirant Limited
OmniSpirant Limited is a biotechnology company focused on developing innovative regenerative gene therapies for respiratory diseases and cancer. Their platform technology, OmniSomes, utilizes inhaled bioengineered stem cell exosomes for efficient intracellular delivery of RNA and protein therapeutics. The company aims to treat currently incurable lung diseases and various cancers through their advanced, first-in-class therapies, leveraging their patented inhaled exosome technology and strategic partnerships. They are committed to transforming medicine by creating therapies that are more effective, less toxic, and accessible.
Industries
Nr. of Employees
small (1-50)
OmniSpirant Limited
Products
Inhaled stem-cell-derived extracellular vesicle therapeutic platform
A platform of mucus-penetrating, stem-cell-derived extracellular vesicles engineered to deliver RNA and protein therapeutics to the lung (also assessed for systemic oncology delivery).
Inhaled stem-cell-derived extracellular vesicle therapeutic platform
A platform of mucus-penetrating, stem-cell-derived extracellular vesicles engineered to deliver RNA and protein therapeutics to the lung (also assessed for systemic oncology delivery).
Services
Partnered co-development of RNA therapeutics using EV delivery
Collaborative development and co-development of RNA therapeutic assets leveraging EV manufacturing and pulmonary delivery expertise.
Partnered co-development of RNA therapeutics using EV delivery
Collaborative development and co-development of RNA therapeutic assets leveraging EV manufacturing and pulmonary delivery expertise.
Expertise Areas
- Regenerative gene therapy
- Extracellular vesicle therapeutics
- Pulmonary drug delivery and aerosol science
- Preclinical respiratory disease modelling
Key Technologies
- Extracellular vesicles (exosomes) for therapeutic delivery
- Vibrating-mesh nebuliser aerosolisation
- Air-liquid interface cell culture models
- Small-animal aerosol administration models